A novel clinical trial recruitment strategy for women's cancers

Rimel, B.J.; Lester, Jenny; Dang, Catherine; Sabacan, Leah; Park, D.; Karlan, Beth Y.

doi:10.1016/j.ygyno.2014.03.373

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite a lack of methodological rigor across most of the studies, those studies that reported positive outcomes generally were those at a system level and included actively prescreening patients and matching them to clinical trials. Having nurses provide tailored summaries of information on clinical trial availability and eligibility to both patients and providers was reported to be associated with increased trial accrual in a pre‐post study 37, 42, 43 . Though presentation at a tumor board was associated with increased likelihood of enrollment in a therapeutic trial, the decision to present at a tumor board is inevitably at the clinician's discretion, so those cases are more likely to be considered for a trial from the outset and any reported benefit is confounded.…”

Section: Discussionmentioning

confidence: 99%

“…Rimel et al. 37 compared a web‐based online registry and trial matching program to a traditional paper‐based registry for gynecological cancer studies. Introduction of the web‐based registry was associated with a substantial increase in the number of women participating in the registry, from 5.4 women per month to 23 women per month.…”

Section: Interventions Targeting Systems‐level Changesmentioning

confidence: 99%

“…Rimel et al 37 . compared a web‐based online registry and trial matching program to a traditional paper‐based registry for gynecological cancer studies.…”

Section: Interventions Targeting Systems‐level Changesmentioning

confidence: 99%

See 2 more Smart Citations

Strategies for increasing accrual in cancer clinical trials: What is the evidence?

Michaels,

Weiss,

Sae‐Hau

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

IntroductionDespite the importance of clinical trial participation among cancer patients, few participate—and even fewer patients from ethnic and racial minoritized groups. It is unclear whether suggested approaches to increase accrual are successful. We conducted a scoping review to identify evidence‐based approaches to increase participation in cancer treatment clinical trials that demonstrated clear increases in accrual. Notably, more stringent than other published reviews, only those studies with comparison data to measure a difference in accrual rates were included.MethodsWe searched PubMed/MEDLINE, Embase, CINAHL, and Web of Science for English‐language articles published from January 1, 2012, to August 8, 2022. Studies were included if they were conducted in the United States, described single or multicomponent interventions, and provided data to measure accrual relative to baseline levels or that compared accrual rates with other interventions.ResultsSixteen articles were included: six with interventions addressing patient barriers, two addressing provider barriers, seven describing institutional change, and one describing policy change. Key themes emerged, such as a focus on patient education, cultural competency, and building the capacity of clinics. Few studies provide comparative accrual data, making it difficult to identify with certainty any effective, evidence‐based approaches for increasing accrual. Some patient‐ and system‐level interventions studies showed modest increases in accrual primarily through pre‐post measurement.ConclusionDespite an extensive body of literature about the barriers that impede cancer treatment trial accrual, along with numerous recommendations for how to overcome these barriers, results reveal surprisingly little evidence published in the last 10 years on interventions that increase accrual relative to baseline levels or compared with other interventions. As clinical trials are a primary vehicle through which we improve cancer care, it is critical that evidence‐based approaches are used to inform all efforts to increase accrual. Strategies for increasing participation in cancer clinical trials must be developed and rigorously evaluated so that these strategies can be disseminated, participation in trials can increase and become more equitable, and trial results can become more generalizable.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Interventions Targeting Systems‐level Changesmentioning

confidence: 99%